.gif){kind=logo}
Monday October 15- PDUFA date for Johnson & Johnson's (NYSE: JNJ) Doripenem for complicated intra-abdominal infection, complicated urinary tract infection
- PDUFA date for Bristol Myers Squibb Company (NYSE: BMY)/Elan Corporation's (NYSE: ELN) Tysabri (Natalizumab), a treatment for moderately to severely active Crohn's Disease
- PDUFA date for Merck & Co Inc's (NYSE: MRK) Januvia (Sitagliptin Phosphate) an adjunct to diet and exercise and as add-on therapy to a sulfonylurea in non-insulin dependent diabetes melliltus (NIDDM)/Type 2 Diabetes; add-on therapy to the combination of a sulfonylurea plus metformin in non-insulin depedent diabetes mellitus (NIDDM)Type 2 diabetes
- PDUFA date for YY (NYSE: NVS) Tasigna (Nilotinib) for chronic myleoid leukemia/acute lymphoblastic leukemia
- Johnson & Johnson to report Q3 earnings; conference call at 8:30am
- Yahoo! Inc (NASDAQ: YHOO) to report Q3 earnings; conference call at 5pm
- Intel Corporation (NASDAQ: INTC) to report Q3 earnings; conference call at 5:30pm
- PDUFA date for Merck's Isentress (Raltegravir), formerly MK-0518, for treatment for Human Immunodeficiency Virus (HIV) infection
- Altria Group Inc (NYSE: MO) to report Q3 earnings; conference call at 9am
- eBay Inc (NASDAQ: EBAY) to report Q3 earnings; conference call at 5pm
- General Motors Corporation (NYSE: GM) to report monthly sales at 9am
- Google Inc (NASDAQ: GOOG) to report Q3 earnings; conference call at 4:30pm.
- Harley Davidson Inc (NYSE: HOG) to report Q3 earnings; conference call at 9am
- PDUFA date for Cardiome Pharma Corporation's (NASDAQ: CRME) IV Vernakalant, an intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation
- PDUFA date for Indevus Pharmaceuticals Inc's (NASDAQ: IDEV) Valstar, for the therapy of bacillus Calmette-Guerin - refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
- PDUFA date for DOR BioPharma Inc's (OTC: DORB) orBec (Oral Beclomethasone Dipropionate) for Gastrointestinal Graft-Vs-Host Disease
- PDUFA date for Bristol Myers Squibb's Ixabepilone; monotherapy to treat patients with metastatic or locally advanced breast cancer after failure of chemotherapies
- PDUFA date for Genentech Inc's (NYSE: DNA)/Roche Holdings Ltd's (OTC: RHHBY) Herceptin (Trastuzumab); in combination with taxotere as first-line treatment of HER-2 positive metastatic breast cancer
Warren Buffett, tells us more!
Oil has dropped $13, so gasoline should drop 30 cents, Americans hope
Wal-Mart's new Supermercado concept could be huge
Reader Comments (Page 1 of 1)
10-12-2007 @ 11:07PM
semi- said...
re PDUFA date 10/15/2007 (Monday) The partners for Tysabri are ELN/BIIB (NOT BMY/ELN)